Yoel, U., Alkobi Weiss, H., Goldbart, A., Silverman Siris, E., Fisher, D. L., Hassan, L., & Fraenkel, M. (2024). The impact of a fracture liaison service with in-hospital anti-osteoporosis treatment on subsequent hip fracture and mortality rates—a single-center retrospective study. Osteoporosis International. https://doi.org/10.1007/s00198-024-07325-9

Cosman, F., Langdahl, B., & Leder, B. Z. (2024). Treatment Sequence for Osteoporosis. Endocrine Practice, 30(5), 490–496. https://doi.org/10.1016/j.eprac.2024.01.014

McClung, M. R., Betah, D., Deignan, C., Shi, Y., Timoshanko, J., & Cosman, F. (2023). Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk. Endocrine Practice, 29(9), 716–722. https://doi.org/10.1016/j.eprac.2023.06.011

Ganapathy, A., Nieves, J. W., Keaveny, T. M., & Cosman, F. (2023). Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis. Bone, 167, 116618. https://doi.org/10.1016/j.bone.2022.116618

Bandeira, F., Oliveira, L. B. de, & Bilezikian, J. P. (2022). Long-term consequences of osteoporosis therapy with denosumab. Archives of Endocrinology and Metabolism, 66(5), 717–723. https://doi.org/10.20945/2359-3997000000560

Cosman, F., Huang, S., McDermott, M., & Cummings, S. R. (2020). Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses. Journal of Bone and Mineral Research, 37(11), 2112–2120. https://doi.org/10.1002/jbmr.4705

LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022). The clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis International, 33(10), 2049–2102. https://doi.org/10.1007/s00198-021-05900-y

Paschalis, E. P., Gamsjaeger, S., Klaushofer, K., Shane, E., Cohen, A., Stepan, J., Pavo, I., Eriksen, E. F., Taylor, K. A., & Dempster, D. W. (2022). Treatment of postmenopausal osteoporosis patients with teriparatide for 24 months reverts forming bone quality indices to premenopausal healthy control values. Bone, 162, 116478. https://doi.org/10.1016/j.bone.2022.116478

Agarwal, S., Shane, E., Lang, T., Shiau, S., Kamanda-Kosseh, M., Bucovsky, M., Lappe, J. M., Stubby, J., Recker, R. R., Hu, Y., Wang, Z., Edward Guo, X., & Cohen, A. (2022). Spine Volumetric BMD and Strength in Premenopausal Idiopathic Osteoporosis: Effect of Teriparatide Followed by Denosumab. The Journal of Clinical Endocrinology & Metabolism, 107(7), e2690–e2701. https://doi.org/10.1210/clinem/dgac232

Cosman, F., Kendler, D. L., Langdahl, B. L., Leder, B. Z., Lewiecki, E. M., Miyauchi, A., Rojeski, M., McDermott, M., Oates, M. K., Milmont, C. E., Libanati, C., & Ferrari, S. (2022). Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporosis International, 33(6), 1243–1256. https://doi.org/10.1007/s00198-021-06174-0

Cosman, F., Cooper, C., Wang, Y., Mitlak, B., Varughese, S., & Williams, S. A. (2022). Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study. Osteoporosis International, 33(8), 1703–1714. https://doi.org/10.1007/s00198-022-06413-y

Shane, E., Shiau, S., Recker, R. R., Lappe, J. M., Agarwal, S., Kamanda-Kosseh, M., Bucovsky, M., Stubby, J., & Cohen, A. (2021). Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis. The Journal of Clinical Endocrinology & Metabolism, 107(4), e1528–e1540. https://doi.org/10.1210/clinem/dgab850

Rooney, A. M., Dempster, D. W., Nieves, J. W., Zhou, H., Bostrom, M. P. G., & Cosman, F. (2022). Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neck. Bone, 157, 116342. https://doi.org/10.1016/j.bone.2022.116342